本帖最后由 greeky 于 2010-2-23 19:45 编辑
5The following appeared in the business section of a newspaper.
"Given that the number of people in our country with some form of arthritis is expected to rise from 40 million to 60 million over the next twenty years, pharmaceutical companies that produce drugs for the treatment of arthritis should be very profitable. Many analysts believe that in ten years Becton Pharmaceuticals, which makes Xenon, the best-selling drug treatment for arthritis, will be the most profitable pharmaceutical company. But the patent on Xenon expires in three years, and other companies will then be able to produce a cheaper version of the drug. Thus, it is more likely that in ten years the most profitable pharmaceutical company will be Perkins Pharmaceuticals, maker of a new drug called Xylan, which clinical studies show is preferred over Xenon by seven out of ten patients suffering from the most extreme cases of arthritis."
Only based on groundless evidence and dubious assumption,the arguer draws a conclusion that for the reason that the number of patients suffering from arthritis will increase,the pharmaceutical companies will be more profitable and Becton company and Perkins company will be the most profitable in a row. At first glance,the conclusion sounds somewhat cogent,nonetheless,a further reflection reveals that it lacks some substantial concerns. From my personal perspective,the argument suffers from three logical flaws.
First of all, the arguer fails to establish a correct cause-and-effect relationship between the fact that the the number of arthritis patients will increase and the claim that pharmaceutical companies dealing with arthritis will be more profitable. The increasing of the patients who suffer from this illness merely means a better sale. Nonetheless,an increase in sale may not make the companies more profitable,there is a myriad of possible occurrence that could prevent the industry becoming more profitable,for instance a fierce competition will compel the companies to invest more money on advertisement and sale the drug in a cheaper price,which can low the margin profit.
The arguer`s claim is unacceptable unless there is a compelling evidence that support the causal relationship between the two events.
Additionally,the arguer asserts that when the patent on Xenon expires in three years, other companies will then be able to produce a cheaper version of the drug.nonetheless,the arguer fails to rule outs some possible negative events in the foreseeable future that may prevent the others company to produce a cheaper version of the drug. Perhaps it is so difficult to imitate the procedure of producing the drug that there are still few companies which are able to produce it. Or the price of the rude material for the producing of the drug is much higher than before,which make it is nearly impossible to sole this drug in a cheaper price.
Finally,if the surveyor did not provide enough samples of patient volunteer and did so randomly across the entire patients who suffers from arthritis,the result of the study would be unacceptable to gauge the actual function of the new drug in dealing with arthritis. The arguer merely tells us that"seven of ten patients",however he neglects to provide the absolute number of volunteer,which make the study unacceptable. If the arguer only indicates that the volunteer are "patients suffering from the most extreme cases of arthritis",it undoubtedly tell that maybe this drug only function to this type of patients. Or if the number of volunteers only account for a very small percentage,the result of the study will also be meaningless.
In sum,the arguer fails to substantiate his claims i have discussed above,because the evidence cited in the argument does not lend strong provide to what the arguer maintains.to be more convincing the arguer would had provided more information with regard to the procedure of the study and the numbers of the patient volunteers. Additionally,he would have to establish a correct causal relationship between the increase of the arthritis patients and the profits of the drug companies that produce drug related with arthritis. If the argument had included the factors discussed above,it would have been more convincing and logically acceptable. |